MUST READ COPIED AND PASTES THIS FROM ANOTHER MESSAGE BOARD BUT ITS EXACTLY WHAT IM TALKING ABOUT.Best way to value GSCG is to look at stock valuations at other stem cell companies for comparison....These examples make it pretty clear we are talking about great greenback dollars comings soon. LAAAAHOOOOOO
Athersys (NASDAQ:ATHX)
Market cap: $226.15 Million; current share price: $1.83
Athersys is a biopharmaceutical focused on its MultiStem programs, which is a stem cell product developed to treat multiple diseases and conditions such as inflammatory bowel disease, congestive heart failure, ischemic stroke and more.
The company announced a new collaboration intent in March with private Japanese company Healios to expand MultiStem further.
“This is a significant opportunity for both Healios and Athersys,” commented Dr. Gil Van Bokkelen, CEO of Athersys. “It provides for a meaningful expansion of the existing partnership, providing a much broader scope of rights for Healios, while providing Athersys with substantial additional capital and a committed development partner in key areas.”
Athersys’ 2017 financial results highlights that its research and development costs increased to $27.8 million from $24.8 million in 2016.
Pluristem Therapeutics (NASDAQSTI)
Market cap: $161.84 million; current share price: $1.47
This clinical-stage biotherapy product develops cell therapy to treat inflammation, ischemia, radiation damage and more. Pluristem develops placenta-derived off-the-shelf products.
Pluristem produces its cells in a one-of-a-kind 3D bioreactor that resembles the environment of the human body, which can generate the cells on a mass scale.
In early 2018, the company received US Food and Drug Administration (FDA) approval to expand its critical limb ischemia outside of its ongoing phase 3 study for the same treatments.
“This is a true vote of confidence by the FDA in our cell therapy and a landmark achievement for Pluristem and its shareholders. It gives us the ability to begin treatments using our cell product, offering treatment to certain CLI patients who have poor therapeutic options, while also collecting real-world data alongside our ongoing phase III clinical study,” Yaky Yanay, Co-CEO and president of Pluristem said in the press release.
Cellular Biomedicine Group (NASDAQ:CBMG)
Market cap: $267.60 million; current share price: $19.10
This company has its eyes set on China as it hopes to become a leader in the specialty pharmaceutical market for cell therapeutics. Late 2017, Cellular Biomedicine opened a new Shanghai-based joint laboratory and manufacturing facility.
Earlier this year, the company additionally announced a new cell therapy manufacturing agreement with GE Healthcare.
“This is a productivity revolution in the CAR-T space,” Tony Liu, CEO of the company said in the release.“This new generation of semi-automated and standardized CAR-T manufacturing capabilities created by GE Healthcare and CBMG may allow cell therapy to provide an optimal platform and opportunity for general oncology patients.”
Vericel (NASDAQ:VCEL)
Market cap: $392.71 million; current share price: $11.25
Vericel bases its treatment in tissue collection from the patient. Its two lead products, Carticel and Epicel, are seeking to treat cartilage defects in the knee and patients with burns greater than or equal to 30 percent of total body surface area respectively.
The company initiated a collaboration with the private company Innovative Cellular Therapeutics. Vericel has the intention to use the collaboration to bring its cell therapy products to patients in Asia.
In March, the company announced positive 2017 financial results with an 18 percent increase to $63.9 million from $54.4 million year over year.
“We successfully executed the launch of MACI and expanded Epicel utilization in 2017,” Nick Colangelo, Vericel president and CEO said. “These successes, combined with a strong balance sheet and an expanded sales force in 2018, have positioned the company for continued strong revenue growth in the years ahead.
